KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $2.4 million.

  • Halozyme Therapeutics' Other Non Operating Income fell 6649.66% to $2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $21.5 million, marking a year-over-year decrease of 959.92%. This contributed to the annual value of $21.5 million for FY2025, which is 959.92% down from last year.
  • Halozyme Therapeutics' Other Non Operating Income amounted to $2.4 million in Q4 2025, which was down 6649.66% from $5.3 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Other Non Operating Income high stood at $7.3 million for Q4 2024, and its period low was -$945000.0 during Q2 2022.
  • Its 5-year average for Other Non Operating Income is $3.2 million, with a median of $3.1 million in 2023.
  • As far as peak fluctuations go, Halozyme Therapeutics' Other Non Operating Income plummeted by 52760.18% in 2022, and later surged by 64664.59% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Other Non Operating Income (Quarter) stood at $331000.0 in 2021, then surged by 157.4% to $852000.0 in 2022, then surged by 529.11% to $5.4 million in 2023, then skyrocketed by 35.32% to $7.3 million in 2024, then plummeted by 66.5% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q4 2025, $5.3 million for Q3 2025, and $6.9 million during Q2 2025.